MAKO Related Analyst Ratings
-
WallachBeth Capital Starts MAKO Surgical (MAKO) at Hold
-
Mizuho Securities Upgrades MAKO Surgical (MAKO) to Buy
-
Nothing Will Change for MAKO Surgical (MAKO) Amid Intuitive (ISRG) Probe
-
Oppenheimer Trims PT on MAKO (MAKO) to $13
-
Goldman Sachs Cuts PT on MAKO (MAKO) to $16 Following Offering
-
With MAKO Surgical (MAKO) Q3 Mixed Canaccord Genuity Maintains Hold
-
Summer Street Upgrades MAKO Surgical (MAKO) to Buy
-
Analysts See Pick Up in 2H Orders at Mako Surgical (MAKO)
-
Wells Fargo Starts MAKO Surgical (MAKO) at Market Perform; Continued Share in Knee, Slowing in Hip
-
Goldman Sachs Maintains a 'Neutral' on MAKO Surgical (MAKO); Updating Estimates
-
Dougherty & Co Downgrades MAKO Surgical (MAKO) to Neutral; Limited Upside From Current Level
-
Canaccord Genuity Q1 Review on MAKO Surgical (MAKO): Shark Week Back in Focus
-
Needham & Company Maintains a 'Hold' on Intuitive Surgical (ISRG); This Isn't MAKO, But Macro Not Helpful
-
Summer Street Downgrades MAKO Surgical (MAKO) to Neutral
-
Dougherty & Co Maintains a 'Buy' on MAKO Surgical (MAKO); Would You Be My Chum?
-
Canaccord Genuity Reiterates a 'Hold' on MAKO Surgical (MAKO); Smelling Blood in the Water
-
Goldman Sachs Downgrades MAKO Surgical (MAKO) to Neutral
-
Dougherty & Co Starts MAKO Surgical (MAKO) at Buy; Valuation Rich...But For A Reason
-
William Blair Upgrades MAKO Surgical (MAKO) to Outperform
-
Goldman Sachs Sees 61% Upside in MAKO (MAKO)
-
Auriga on Healthcare Services: MAKO Misses 1Q12 Expectations; Read-through for HMA
-
Canaccord Genuity Cuts Numbers on MAKO Surgical (MAKO); Q1 Brought Down By Weak Systems Sales
-
Mizuho Securities Downgrades MAKO Surgical (MAKO) to Neutral
-
William Blair Downgrades MAKO Surgical (MAKO) to Market Perform
-
Oppenheimer Starts MAKO Surgical (MAKO) at Perform, Cites Valuation
-
Mizuho Securities Starts MAKO Surgical (MAKO) at Buy
-
Canaccord Genuity Maintains a 'Hold' on MAKO Surgical (MAKO); Solid Knee, Slow Hip
-
Goldman Sachs Lifts Price Target on MAKO Surgical (MAKO) Following Q4
-
Canaccord Genuity maintains a 'Hold' on MAKO Surgical (MAKO); Raising Q4 Revenuess, Lowering 2012 to Reflect Pre-announcement
-
Canaccord Genuity Q4/11 Orthopedic Preview: Four Movers Over The Next Six Months
-
Summer Street Upgrades MAKO Surgical (MAKO) to Buy
-
Canaccord Genuity Reiterates a 'Hold' on MAKO Surgical (MAKO); Q3/11 Results In Line; Systems Light, Utilization Strong, Hip Just Starting
-
Leerink Swann Raises Valuation on MAKO Surgical (MAKO), Weak Margins Within Hip Market
-
Leerink Swann Maintains a 'Market Perform' on MAKO Surgical (MAKO); Adjusting Estimates Post-Hip Launch
-
Goldman Sachs Removes MAKO Surgical (MAKO) from Conviction Buy List
-
Summer Street Starts NUVA, ANIK, TRNX, TSON, BMTI, ATEC at Buy, MAKO at Neutral
-
Canaccord Genuity on Life Sciences - Biomedical Devices and Services: Q2/11 Orthopedic Preview
-
Morgan Stanley Starts MAKO Surgical (MAKO) at Equalweight
-
UPDATE - Canaccord Genuity Initiates Coverage on MAKO Surgical (MAKO) with a Hold; Knee is Driving Growth; Hip Too Early to Call
-
Canaccord Genuity Starts MAKO Surgical (MAKO) at Hold
-
Goldman Sachs Lifts Price Target on MAKO Surgical (MAKO), Keeps Top Rating
-
William Blair Starts MAKO Surgical (MAKO) at Outperform; Aggressive Growth Cmpany Pofile
-
Goldman Sachs Removes Alexion Pharmaceuticals (ALXN) from Conviction Buy List
-
Goldman Sachs Starts MAKO Surgical (MAKO) at Conviction Buy, Sees 43% Upside
-
Brigantine Advisors Reiterates a 'Buy' on MAKO Surgical (MAKO); Growth Trajectory Intact
-
Brigantine Advisors Healthcare Industry Note: Review of 2010 Healthcare Sector Performance & Top Picks for 2011
-
JPMorgan Names 2011's Best, Worst Picks for MedTech Sector (STJ, COV, PODD, BMTI, more)
-
JPMorgan Downgrades MAKO Surgical (MAKO) to Neutral
-
BioLogic Equity Research Downgrades MAKO Surgical (MAKO) to Sell
-
Brigantine Initiates Coverage on MAKO Surgical (MAKO) with a Buy
Back to MAKO Stock Lookup
